<code id='D99EF6E298'></code><style id='D99EF6E298'></style>
    • <acronym id='D99EF6E298'></acronym>
      <center id='D99EF6E298'><center id='D99EF6E298'><tfoot id='D99EF6E298'></tfoot></center><abbr id='D99EF6E298'><dir id='D99EF6E298'><tfoot id='D99EF6E298'></tfoot><noframes id='D99EF6E298'>

    • <optgroup id='D99EF6E298'><strike id='D99EF6E298'><sup id='D99EF6E298'></sup></strike><code id='D99EF6E298'></code></optgroup>
        1. <b id='D99EF6E298'><label id='D99EF6E298'><select id='D99EF6E298'><dt id='D99EF6E298'><span id='D99EF6E298'></span></dt></select></label></b><u id='D99EF6E298'></u>
          <i id='D99EF6E298'><strike id='D99EF6E298'><tt id='D99EF6E298'><pre id='D99EF6E298'></pre></tt></strike></i>

          leisure time

          leisure time

          author:knowledge    Page View:2611
          Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT
          Adobe

          In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

          Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

          advertisement

          Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

          For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more
          At flashy new research hub, AstraZeneca lays out ambitious growth goals
          At flashy new research hub, AstraZeneca lays out ambitious growth goals

          PascalSoriothasservedasCEOofAstraZenecasince2012.WinMcNamee/GettyImagesCAMBRIDGE,England—Onabitofaro

          read more
          Guidelines to prevent youth baseball injuries need more muscle
          Guidelines to prevent youth baseball injuries need more muscle

          Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

          read more

          AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

          RubyWallauforSTATAbbViewillpay$10billionforthebiotechfirmImmunogen,thecompanysaidThursday,acquiringa